Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:56 AM
Ignite Modification Date:
2025-12-25 @ 4:56 AM
NCT ID:
NCT05606718
Eligibility Criteria:
Inclusion Criteria:
* Patients aged \>18 years and \<90 years
* LVEF\<60% and EROA of mitral regurgitationā„0.2cm2 on echocardiography
* The structure of mitral valve leaf and chordae tendineae is normal
* Patients have received GDMT for FMR including a stable, optimized dose of Ī²-blocker and RAAS inhibitors for at least 2 weeks
Exclusion Criteria:
* Allergic to dapagliflozin, or angioedema
* Already taking dapagliflozin or other SGLT2 inhibitors
* Presence of primary structural damage to the mitral valve, such as rheumatic heart disease, mitral valve prolapses
* Non-dialysis chronic kidney disease (CKD) patients with eGFR \<30ml/min/1.73m2 or dialysis patients
* Acute myocardial infarction and acute myocarditis occurred within 3 months
* Revascularization procedure, CRT, TMVR, surgical valve repair or replacement were performed or planed 3 months before or after enrollment
* Combining significant aortic valve diseases (moderate or severe regurgitation or stenosis)
* Combining hyperthyroidism while thyroid function has not returned to normal
* Pregnant or lactation women
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
90 Years
Study:
NCT05606718
Study Brief:
Protocol Section:
NCT05606718